SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelderman Kim

(Last)

(First)

(Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS

MINNESOTA

55413

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/15/2026		M		21,470	A	$0	93,583	D
Common Stock	08/15/2026		F		10,821	D	$72.4	82,762	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$66.97							⁽¹⁾	08/05/2027	Common Stock	115,724		115,724	D
Stock Option (Right to Buy)	$120.46							⁽¹⁾	08/06/2028	Common Stock	25,944		25,944	D
Stock Options (Right to Buy)	$94.52							⁽¹⁾	08/15/2029	Common Stock	28,940		28,940	D
Performance Restricted Stock Units	⁽²⁾	08/15/2026		M			554	⁽³⁾	⁽³⁾	Common Stock	554	$0	8,319	D
Performance Restricted Stock Units	⁽²⁾	08/15/2026		D			8,319	⁽³⁾	⁽³⁾	Common Stock	8,319	$0	0	D
Performance Stock Options (Right to Buy)	$84.61	08/15/2026		D			22,389	⁽⁴⁾	08/15/2030	Common Stock	22,389	$0	1,492	D
Stock Options (Right to Buy)	$84.61							⁽⁵⁾	08/15/2030	Common Stock	29,391		29,391	D
Stock Options (Right to Buy)	$52.83							⁽⁶⁾	11/01/2030	Common Stock	38,252		38,252	D
Performance Restricted Stock Units	⁽²⁾	08/15/2026		M			588	⁽⁷⁾	⁽⁷⁾	Common Stock	588	$0	8,835	D
Performance Restricted Stock Units	⁽²⁾	08/15/2026		D			8,835	⁽⁷⁾	⁽⁷⁾	Common Stock	8,835	$0	0	D
Performance Stock Options (Right to Buy)	$68.54	08/15/2026		D			24,324	⁽⁸⁾	02/01/2031	Common Stock	24,324	$0	1,621	D
Stock Options (Right to Buy)	$68.54							⁽⁹⁾	02/01/2031	Common Stock	51,890		51,890	D
Performance Restricted Stock Units	⁽²⁾							⁽¹⁰⁾	⁽¹⁰⁾	Common Stock	51,261		51,261	D
Restricted Stock Units	⁽²⁾	08/15/2026		M			8,543	⁽¹¹⁾	⁽¹¹⁾	Common Stock	8,543	$0	8,544	D
Stock Options (Right to Buy)	$74.91							⁽¹²⁾	08/15/2034	Common Stock	69,061		69,061	D
Performance Restricted Stock Units	⁽²⁾							⁽¹³⁾	⁽¹³⁾	Common Stock	70,708		70,708	D
Restricted Stock Units	⁽²⁾	08/15/2026		M			11,785	⁽¹⁴⁾	⁽¹⁴⁾	Common Stock	11,785	$0	23,569	D
Stock Options (Right to Buy)	$53.6							⁽¹⁵⁾	08/15/2035	Common Stock	90,441		90,441	D

Explanation of Responses:

1. Fully exercisable.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

3. On 8/15/2026, the Board of Directors authorized discretionary vesting for 554 performance RSUs. The remainder of the performance RSUs were forfeited.

4. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,492 performance options. The remainder of the performance options were forfeited.

5. Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.

6. Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.

7. On 8/15/2026, the Board of Directors authorized discretionary vesting for 588 performance RSUs. The remainder of the performance RSUs were forfeited.

8. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,621 performance options. The remainder of the performance options were forfeited.

9. Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.

10. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

11. 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.

12. Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.

13. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

14. 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.

15. Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.

	/s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed.	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)